Flagship Ventures CEO keeps Merck aboard to inform biotech bets

Flagship Ventures CEO keeps Merck aboard to inform biotech bets

September 25, 2012

Largely gone are the days when venture capitalists could hatch a biotech and take it public without much regard for the needs of Big Pharma. Public investors seldom buy into new biotech companies, and drugmakers have increasingly become early partners with VC firms and their young ventures. In the process, pharma has gained significant clout in the biotech VC game.

The Energy Of The Future Is Here: AeroShot Energy, New "Air-Based" Energy Product Launches Nationwide

The Energy Of The Future Is Here: AeroShot Energy, New "Air-Based" Energy Product Launches Nationwide

September 20, 2012

AeroShot Energy, a revolutionary air-based energy product invented by Harvard professor David Edwards, will launch across the United States on October 1st.

Black Duck Software Named to Software Magazine's 30th Annual Software 500

Black Duck Software Named to Software Magazine's 30th Annual Software 500

September 20, 2012

Software Magazine Ranks Black Duck as one of the World's Largest and Fastest Growing Software Companies

BURLINGTON, Mass., Sept. 20, 2012 /PRNewswire via COMTEX/ -- Black Duck Software today announced its inclusion in Software Magazine's Software 500 ranking of the world's largest software and service providers, now in its 30th year.

BIND Biosciences Appoints Industry Veteran Daniel Lynch as Chairman of the Board of Directors

BIND Biosciences Appoints Industry Veteran Daniel Lynch as Chairman of the Board of Directors

September 20, 2012

CAMBRIDGE, Mass., Sep 20, 2012 (BUSINESS WIRE) -- BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins(TM), today announced the appointment of Daniel S. Lynch as Chairman of the company's board of directors.

Joule Partners with Audi to Accelerate Development and Commercialization of Sustainable, Carbon-Neutral Fuels

Joule Partners with Audi to Accelerate Development and Commercialization of Sustainable, Carbon-Neutral Fuels

September 17, 2012

BEDFORD, Mass.--(BUSINESS WIRE)--

Tangent Medical Receives FDA Clearance for the NovaCath™ Secure IV Catheter System

Tangent Medical Receives FDA Clearance for the NovaCath™ Secure IV Catheter System

September 13, 2012

ANN ARBOR, Mich., Sept. 13, 2012 /PRNewswire/ -- Tangent Medical (www.tangentmedical.com), an innovator in IV therapy products, today announced it has received FDA 510(k) clearance for the NovaCath™ Secure IV Catheter System, a product designed to set new standards in peripheral IV catheter design, functionality and performance.

LS9 Announces Successful Start-up of Florida Demonstration Facility

LS9 Announces Successful Start-up of Florida Demonstration Facility

September 10, 2012

First Production Run Achieves Technical Goals

Joule Commissions First SunSprings™ Plant to Demonstrate Commercial Readiness

Joule Commissions First SunSprings™ Plant to Demonstrate Commercial Readiness

September 11, 2012

BEDFORD, Mass.--(BUSINESS WIRE)--

Visterra Appoints Donna M. Ambrosino as Chief Medical Officer

Visterra Appoints Donna M. Ambrosino as Chief Medical Officer

September 11, 2012

CAMBRIDGE, Mass., Sep 11, 2012 (BUSINESS WIRE) -- Visterra, Inc., developer of novel therapeutics to treat major diseases, announced today that it has appointed Donna M. Ambrosino, M.D., as chief medical officer. Dr. Ambrosino will oversee all drug development activities for the company, including the company's lead drug candidate against influenza, VIS410, and she will serve as a member of the company's executive management team.

Visterra Signs Antibody Discovery Collaboration Deal With Pfizer

Visterra Signs Antibody Discovery Collaboration Deal With Pfizer

September 11, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Visterra Inc., developer of novel therapeutics to treat major diseases, announced today that it has entered into a collaboration agreement with Pfizer to discover novel antibodies using Visterra’s proprietary platform.